Overexpression of FAK has been clinically observed in primary human sarcomas [119], human prostate carcinomas [120], human ovary carcinomas [121], human colorectal carcinomas [122], and breast cancers [123], implicating the role of FAK in cancer development. Here, PTK2 is linked to ovarian carcinoma.